Effect of hydroxyurea treatment on renal function parameters: Results from the multi‐center placebo‐controlled BABY HUG clinical trial for infants with sickle cell anemia

• DOI: 10.1002/pbc.24100
• Publication Date: 2012-01-31T15:49:10Z
• Authors: Ofelia Alvarez; Scott T. Miller; Winfred C. Wang; Zhaoyu Luo; M. Beth McCarville; George J. Schwartz; Bruce Thompson; Thomas Howard; Rathi V. Iyer; Sohail R. Rana; Zora R. Rogers; Sharada A. Sarnaik; Courtney D. Thorn...; Russell E. Ware
• Keywords: Urine osmolality; Osmole

Abstract Background Children with sickle cell anemia (SCA) often develop hyposthenuria and renal hyperfiltration at an early age, possibly contributing to the glomerular injury insufficiency commonly seen later in life. The Phase III randomized double‐blinded Clinical Trial of Hydroxyurea Infants SCA (BABY HUG) tested hypothesis that hydroxyurea can prevent kidney dysfunction by reducing hyperfiltration. Procedure 193 infants (mean age 13.8 months) received 20 mg/kg/day or placebo for 24 months. 99m Tc diethylenetriaminepentaacetic acid (DTPA) clearance, serum creatinine, cystatin C, urinalysis, urine osmolality after parent‐supervised fluid deprivation, ultrasonography were obtained baseline exit measure treatment effects on function. Results At children treated had significantly higher 495 mOsm/kg H 2 O compared 452 group, P = 0.007) a larger percentage subjects taking achieved >500 O. Moreover, smaller volumes ( 0.007). DTPA‐derived filtration rate (GFR) was not different between two groups, but than published norms. GFR estimated Chronic Kidney Disease (CKiD) Schwartz formula best non‐invasive method estimate these children, as it closest GFR. Conclusion Treatment months did influence young SCA. However, associated better concentrating ability less enlargement, suggesting some benefit (ClinicalTrials.gov number NCT00006400) Pediatr Blood Cancer 2012;59:668–674. © 2012 Wiley Periodicals, Inc.